Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 May;32(5):423-424.
doi: 10.1038/s41422-022-00637-7.

Banking on metabolomics for novel therapies in TNBC

Aurelien Tripp  1 , George Poulogiannis  2
Affiliations
Comment

Banking on metabolomics for novel therapies in TNBC

Aurelien Tripp et al. Cell Res. 2022 May.
No abstract available

PubMed Disclaimer

Figures

Fig. 1
Fig. 1. A new pipeline for targeted therapies for treatment-refractory TNBCs.
Work from Xiao et al. could suggest a new pipeline integrating multiple approaches to treat patients with TNBC. Following biopsy or surgical resection of a tumor, immunohistochemistry (IHC) using a panel of four markers could stratify patients in one of four transcriptome-based subtypes. Targeting metabolic vulnerabilities specific to treatment-refractory TNBC subtypes could enable individual-tailored treatment regimens.
See this image and copyright information in PMC

Comment on

References

    1. Denkert C, et al. Lancet. 2017;389:2430–2442. doi: 10.1016/S0140-6736(16)32454-0. - DOI - PubMed
    1. Lyons TG. Curr. Treat. Options Oncol. 2019;20:82. doi: 10.1007/s11864-019-0682-x. - DOI - PubMed
    1. Lehmann BD, et al. J. Clin. Invest. 2011;121:2750–2767. doi: 10.1172/JCI45014. - DOI - PMC - PubMed
    1. Jezequel P, et al. Breast Cancer Res. 2019;21:65. doi: 10.1186/s13058-019-1148-6. - DOI - PMC - PubMed
    1. He Y, et al. J. Exp. Clin. Cancer Res. 2018;37:327. doi: 10.1186/s13046-018-1002-1. - DOI - PMC - PubMed